In March 2009, Merit Medical Systems, Inc. acquired the products formerly manufactured and distributed by Alveolus, Inc. This acquisition introduces a new division, Merit Endotek™, which integrates non-vascular stent technology with inflation devices, guide wires, and other accessories used throughout the medical community. Prior to the acquisition by Merit, Alveolus developed next-generation stent technology for use in the airway (AERO®), esophagus (ALIMAXX-ES®), and biliary tract (ALIMAXX-B®) to build value and quality in the creation of interventional and palliative treatment alternatives.
Since the very beginning, Merit Endotek has focused on expanding the boundaries of interventional and palliative medicine. This started with ALIMAXX-ES, the world’s first FDA cleared, fully covered esophageal stent. It includes AERO, a uniquely trusted and capable tracheobronchial stent. And it features a long list of other groundbreaking products—from the revolutionary BIG60 inflation device for pulmonary and gastroenterology balloon dilation to a complete family of integrated guide wires, negative pressure syringes, bipolar probes, and other solutions.
Today, Merit Endotek continues to expand this legacy of innovation and quality with a sharp focus on creative problem solving, a passion for listening and responding to our customers, and a commitment to developing groundbreaking new technology that enables clinicians to achieve the best possible clinical outcomes for their patients.
This approach has led to the launch of six innovative and successful new products since 2009. And it will allow us to continue to push the boundaries of innovation and performance for our customers in the years to come.
Darla Gill is one of the founders of Merit Medical, serving early in 1988 as its Executive Vice President of Marketing and Sales and as a Director on the Company’s Board. Since 2009, she has served as President of Merit Endotek, a division that develops, manufactures, and distributes nonvascular stents and other products designed for the treatment of strictures in the gastrointestinal tract and the airway. Gill has worked in the medical device industry since 1983 and has served as a Director on several company boards. She was an executive at Utah Medical Systems from 1983–1988. In 1992, Gill founded Momentum Medical and led the company until its sale in 1998. At that time, Gill returned to Merit Medical as Executive Vice President of New Business Development. From 1999 to 2005, she served as Executive Vice President of Merit Medical Europe where she managed the Company’s marketing, sales, logistics, and customer service in Europe, the Middle East, and Africa. In 2006, Gill was appointed Executive Vice President of Human Resources and Organizational Development of the Company. From 2007–2009, Gill was Executive Vice President of Marketing. She graduated from the University of Phoenix with a bachelor’s degree in Business Administration in 1988.
David Hamilton joined Merit Medical Endotek in June 2009 following the acquisition of Alveolus, Inc., a provider of non-vascular stent technology. As a Director, Hamilton was responsible for Endotek’s EMEA sales and marketing initiatives and worked closely with the US Sales and management team on operational, contractual, and strategic matters. In 2014, Hamilton became Vice President, Sales, and in 2017, he was promoted to his current position as Executive VP of Sales & Marketing. Prior to joining Alveolus, Hamilton was a lawyer working in Scotland.